The screening performed using patient sera from either epithelial tumors (pancreatic cancer, n = 43; breast cancer, n = 43) or hematopoietic malignancies (B-cell chronic lymphocytic leukemia, n = 53 and multiple myeloma, n = 46) showed a significant presence of auto-Abs against ADAM10 in pancreatic and breast cancer, but not in B-CLL and multiple myeloma (SM-Figure 2 and SM-Table 5), which in turn suggested that the reactivity against ADAM10 might be a marker of epithelial tumors. Here, ADAM10 is linked to pancreatic neoplasm.